Migraine Acute Treatment: Gepants, Ditans, and Triptan Comparison
Triptans: The Established Standard
Triptans (5-HT1B/1D agonists) remain the most effective acute migraine treatment class for most patients. Sumatriptan 100 mg oral achieves pain freedom at 2 hours in approximately 30-35% of patients, with rizatriptan 10 mg and eletriptan 40 mg showing modestly higher 2-hour pain-free rates of 35-40% in network meta-analyses. Triptans are contraindicated in patients with established cardiovascular disease, uncontrolled hypertension, hemiplegic migraine, or basilar migraine due to their vasoconstrictive properties. Approximately 30-40% of migraine patients have contraindications to or insufficient response to triptans, creating a significant unmet need that gepants and ditans now address.
Gepants: CGRP Receptor Antagonists
Two oral gepants are approved for acute migraine treatment: ubrogepant (50 mg and 100 mg) and rimegepant (75 mg ODT). In the ACHIEVE I trial, ubrogepant 100 mg achieved 2-hour pain freedom in 21.2% versus 11.8% placebo (p < 0.001) and 2-hour most bothersome symptom (MBS) freedom in 37.7% versus 27.8%. Rimegepant 75 mg achieved 2-hour pain freedom in 19.6% versus 12.0% placebo. While these pain-free rates are numerically lower than triptans, gepants offer critical advantages: no vasoconstrictive properties (safe in cardiovascular disease), no risk of medication overuse headache (MOH), and rimegepant has dual approval for both acute treatment and preventive use (every other day dosing). The most common adverse effects are nausea (2-4%) and somnolence (1-2%), with no triptan-like chest tightness or paresthesias.
Lasmiditan: The First Ditan
Lasmiditan (Reyvow), a selective 5-HT1F agonist, activates serotonin receptors involved in trigeminal pain signaling without vasoconstrictive 5-HT1B effects. The SAMURAI and SPARTAN trials demonstrated 2-hour pain freedom rates of 28-32% for lasmiditan 200 mg versus 15-16% placebo. The primary limitation is CNS side effects: dizziness (15-17%), somnolence (5-6%), and paresthesias (5-7%), with an 8-hour driving restriction after dosing. Lasmiditan is classified as a Schedule V controlled substance due to its subjective effects profile, though abuse potential appears low. It is best positioned for patients with cardiovascular contraindications to triptans who tolerate CNS effects and do not need to drive after treatment.
Sponsored
Head-to-Head Data and Positioning
Direct comparison data remain limited. The Phase 4 COURAGE trial is evaluating ubrogepant versus eletriptan head-to-head. Indirect treatment comparisons and network meta-analyses consistently rank triptans (particularly eletriptan, rizatriptan, and sumatriptan) as having the highest acute efficacy, followed by lasmiditan, then gepants. However, efficacy is only one dimension: consistency of response, tolerability, safety profile, and patient-reported satisfaction must all inform selection. Patients with cardiovascular disease or multiple vascular risk factors should receive gepants or lasmiditan. Patients prioritizing avoiding MOH may benefit from gepants. Patients with infrequent, severe attacks and no vascular contraindications may prefer triptans for maximal acute efficacy.
Combination and Multi-Mechanism Approaches
Combining a triptan with an NSAID (sumatriptan 85 mg/naproxen 500 mg, available as Treximet) achieves 2-hour pain-free rates of approximately 35-40%, superior to either agent alone. Emerging practice includes combining a gepant with a triptan for refractory attacks, though formal trial data for this combination are limited. Patients should treat early (within 1 hour of onset) for maximal efficacy across all drug classes. For patients with medication overuse headache (using acute treatments 10-15 or more days per month), transitioning to gepant-based acute therapy combined with preventive therapy (CGRP monoclonal antibody, gepant prophylaxis, or neuromodulation) is the recommended approach to break the MOH cycle.
Sponsored
Want to try Ailva?
Ailva is a clinical intelligence platform that delivers evidence-based answers with verified citations and cross-system reasoning. Free for all NPI holders.